CD4 and Opportunistic infection: It presents a cost profile differentiated by initiation of treatment at different CD4 cell count levels; time on treatment; cost components (e.g., drug and personnel costs) for HIV care and opportunistic infections (OIs); and finally patient costs of seeking and undergoing care.